 CAMBRIDGE, Mass., Oct. 07, 2021 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. NASDAQ:MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today announced that XMT-2056, its first Immunosynthen STING-agonist ADC candidate, targets a novel epitope of human epidermal growth factor receptor 2 HER2 and presented new preclinical data during a plenary session at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics Triple Meeting. 